Fusion Antibodies PLC (FAB) - Total Liabilities

Latest as of September 2025: GBX1.09 Million GBX ≈ $132.13 USD

Based on the latest financial reports, Fusion Antibodies PLC (FAB) has total liabilities worth GBX1.09 Million GBX (≈ $132.13 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Fusion Antibodies PLC cash conversion from operations to assess how effectively this company generates cash.

Fusion Antibodies PLC - Total Liabilities Trend (2006–2025)

This chart illustrates how Fusion Antibodies PLC's total liabilities have evolved over time, based on quarterly financial data. See what is Fusion Antibodies PLC's book value for net asset value and shareholders' equity analysis.

Fusion Antibodies PLC Competitors by Total Liabilities

The table below lists competitors of Fusion Antibodies PLC ranked by their total liabilities.

Company	Country	Total Liabilities
East Star Resources PLC LSE:EST	UK	GBX83.00K
Oriole Resources PLC LSE:ORR	UK	GBX4.20 Million
Centaur Media LSE:CAU	UK	GBX16.50 Million
Sprott Physical Uranium Trust TO:U-U	Canada	$109.44 Million
noco-noco Inc. Ordinary Share NASDAQ:NCNC	USA	$7.61 Million
Graphjet Technology NASDAQ:GTI	USA	$20.93 Million
Afine Investments Ltd JSE:ANI	South Africa	ZAC110.51 Million

Liability Composition Analysis (2006–2025)

This chart breaks down Fusion Antibodies PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Fusion Antibodies PLC.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.80	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.50	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.60	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Fusion Antibodies PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Fusion Antibodies PLC (2006–2025)

The table below shows the annual total liabilities of Fusion Antibodies PLC from 2006 to 2025.

Year	Total Liabilities	Change
2025-03-31	GBX654.00K ≈ $79.57	+4.31%
2024-03-31	GBX627.00K ≈ $76.29	-33.23%
2023-03-31	GBX939.00K ≈ $114.25	-23.72%
2022-03-31	GBX1.23 Million ≈ $149.78	+13.67%
2021-03-31	GBX1.08 Million ≈ $131.77	-11.81%
2020-03-31	GBX1.23 Million ≈ $149.41	+38.21%
2019-03-31	GBX888.53K ≈ $108.11	+40.24%
2018-03-31	GBX633.59K ≈ $77.09	+40.73%
2017-03-31	GBX450.22K ≈ $54.78	+9.43%
2016-03-31	GBX411.43K ≈ $50.06	+104.01%
2015-03-31	GBX201.67K ≈ $24.54	-32.23%
2014-03-31	GBX297.57K ≈ $36.21	+17.35%
2013-03-31	GBX253.56K ≈ $30.85	-42.76%
2012-03-31	GBX443.00K ≈ $53.90	+15.97%
2011-03-31	GBX382.00K ≈ $46.48	+25.25%
2010-03-31	GBX305.00K ≈ $37.11	-51.82%
2009-03-31	GBX633.00K ≈ $77.02	+37.01%
2008-03-31	GBX462.00K ≈ $56.21	+3.36%
2007-03-31	GBX447.00K ≈ $54.39	+54.14%
2006-03-31	GBX290.00K ≈ $35.28	--

About Fusion Antibodies PLC

LSE:FAB UK Biotechnology

Market Cap

$193.60K

GBX1.59 Billion GBX

Market Cap Rank

#30829 Global

#1022 in UK

Share Price

GBX14.00

Change (1 day)

+0.00%

52-Week Range

GBX5.80 - GBX19.25

All Time High

GBX213.00